110 related articles for article (PubMed ID: 1826449)
1. The polymerase chain reaction: a new tool for the detection of minimal residual disease in haematological malignancies.
Fey MF; Kulozik AE; Hansen-Hagge TE; Tobler A
Eur J Cancer; 1991; 27(1):89-94. PubMed ID: 1826449
[TBL] [Abstract][Full Text] [Related]
2. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
3. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia.
Matsushita M; Ikeda H; Kizaki M; Okamoto S; Ogasawara M; Ikeda Y; Kawakami Y
Br J Haematol; 2001 Mar; 112(4):916-26. PubMed ID: 11298586
[TBL] [Abstract][Full Text] [Related]
4. Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction.
Drexler HG; Borkhardt A; Janssen JW
Leuk Lymphoma; 1995 Nov; 19(5-6):359-80. PubMed ID: 8590836
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction.
Lion T; Izraeli S; Henn T; Gaiger A; Mor W; Gadner H
Leukemia; 1992 Jun; 6(6):495-9. PubMed ID: 1602787
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction.
van Dongen JJ; Breit TM; Adriaansen HJ; Beishuizen A; Hooijkaas H
Leukemia; 1992; 6 Suppl 1():47-59. PubMed ID: 1548936
[TBL] [Abstract][Full Text] [Related]
7. Application of the polymerase chain reaction for detection of minimal residual disease of hematologic malignancies.
Roth MS; Terry VH
Henry Ford Hosp Med J; 1991; 39(2):112-6. PubMed ID: 1890004
[TBL] [Abstract][Full Text] [Related]
8. Pattern of T-cell receptor delta gene rearrangement by Southern blotting and polymerase chain reaction technique in Hong Kong Chinese patients with non-T-cell hematological malignancies.
Chan DW; Liang R; Kwong YL
Hematol Oncol; 1996 Jun; 14(2):57-66. PubMed ID: 8876635
[TBL] [Abstract][Full Text] [Related]
9. Monitoring disease in lymphoma and CLL patients using molecular techniques.
Gribben JG
Best Pract Res Clin Haematol; 2002 Mar; 15(1):179-95. PubMed ID: 11987923
[TBL] [Abstract][Full Text] [Related]
10. [Detection of minimal residual leukemia using polymerase chain reaction method].
Naoe T
Rinsho Byori; 1996 Jun; 44(6):535-40. PubMed ID: 8752731
[TBL] [Abstract][Full Text] [Related]
11. [Residual disease: the hematologist's point of view].
Quesnel B; Preudhomme C
Bull Cancer; 2001 Jun; 88(6):571-5. PubMed ID: 11459703
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
[TBL] [Abstract][Full Text] [Related]
13. [Molecular diagnosis of leukemia and lymphoma].
Iida S; Ueda R
Rinsho Byori; 1994 Apr; 42(4):364-71. PubMed ID: 8176845
[TBL] [Abstract][Full Text] [Related]
14. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review.
Potter MN; Cross NC; van Dongen JJ; Saglio G; Oakhill A; Bartram CR; Goldman JM
Leukemia; 1993 Aug; 7(8):1302-14. PubMed ID: 8350633
[TBL] [Abstract][Full Text] [Related]
15. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction.
Mitterbauer G; Nemeth P; Wacha S; Cross NC; Schwarzinger I; Jaeger U; Geissler K; Greinix HT; Kalhs P; Lechner K; Mannhalter C
Br J Haematol; 1999 Sep; 106(3):634-43. PubMed ID: 10468851
[TBL] [Abstract][Full Text] [Related]
16. [Use of polymerase chain reaction (PCR) in oncohematology. Detection of minimal residual disease].
Kotliar N; Koziner B
Medicina (B Aires); 1995; 55(2):159-66. PubMed ID: 7565055
[TBL] [Abstract][Full Text] [Related]
17. [Polymerase chain reaction (PCR)--a novel tool for the molecular diagnosis of neoplasms].
Yokota S; Abe T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1395-401. PubMed ID: 2202261
[TBL] [Abstract][Full Text] [Related]
18. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
20. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
